구조모아 (StructureMoa)항암 chemical structure spider web
방문분석
큐레이션 브리핑
경쟁 포지션: TROP2 class leader by approval history; now facing Datroway and other TROP2 ADCs.
기전. Anti-TROP2 antibody binds and internalizes; the hydrolyzable linker releases SN-38 both intracellularly and in the tumor microenvironment, inhibiting topoisomerase I and causing lethal DNA double-strand breaks.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
TROP2
Metastatic triple-negative breast cancer, pretreated HR+/HER2− breast cancer
US, EU, JP
Approved
trodelvy · sacituzumab govitecan · Trodelvy · IMMU-132 · sacituzumab-govitecan-hziy
2026-09-10
Data Confidence · High
Development Signal · Established
Antibody-drug conjugate
SN-38 (topoisomerase I inhibitor)
Hydrolyzable CL2A, DAR ~7.6
Humanized anti-TROP2 IgG1 (hRS7)
Very high DAR plus a deliberately unstable linker — extracellular SN-38 release gives bystander killing in TROP2-heterogeneous tumors.
구조화 데이터
Very high DAR plus a deliberately unstable linker — extracellular SN-38 release gives bystander killing in TROP2-heterogeneous tumors.
TROP2 downregulation, TOP1 mutation, and ABC-transporter payload efflux.
SN-38 (topoisomerase I inhibitor)
Hydrolyzable CL2A, DAR ~7.6
DAR 7.6
TROP2 · TROP2 is broadly expressed in epithelial tumors; no companion diagnostic is required in the label.
Manage neutropenia and diarrhea; UGT1A1 poor metabolizers at higher risk
TROP2 class leader by approval history; now facing Datroway and other TROP2 ADCs.
Unresectable locally advanced or metastatic TNBC after ≥2 prior therapies
2L+ TNBC; 3L+ HR+/HER2−
IV
10 mg/kg days 1 and 8 of a 21-day cycle
ORR ~35% in ASCENT
Manage neutropenia and diarrhea; UGT1A1 poor metabolizers at higher risk
TROP2 class leader by approval history; now facing Datroway and other TROP2 ADCs.
Anti-TROP2 antibody binds and internalizes; the hydrolyzable linker releases SN-38 both intracellularly and in the tumor microenvironment, inhibiting topoisomerase I and causing lethal DNA double-strand breaks.
immune-mediated antitumor effects regardless of tumor PD-L1 expression
Topoisomerase I inhibition → replication-fork collapse and apoptosis.
TROP2 is broadly expressed in epithelial tumors; no companion diagnostic is required in the label.
TROP2 downregulation, TOP1 mutation, and ABC-transporter payload efflux.
구조화 데이터
mice bearing HCC1806 TNBC xenograft
Human
ADC ~16 h; free SN-38 ~18 h
ORR and PFS; ctDNA dynamics exploratory
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA accelerated approval (mTNBC)
APPROVAL · 2020년 4월
FDA full approval on ASCENT
APPROVAL · 2021년 4월
HR+/HER2− breast cancer indication
APPROVAL · 2023년 2월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
분석
큐레이션 브리핑
경쟁 포지션: TROP2 class leader by approval history; now facing Datroway and other TROP2 ADCs.
기전. Anti-TROP2 antibody binds and internalizes; the hydrolyzable linker releases SN-38 both intracellularly and in the tumor microenvironment, inhibiting topoisomerase I and causing lethal DNA double-strand breaks.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
TROP2
Metastatic triple-negative breast cancer, pretreated HR+/HER2− breast cancer
US, EU, JP
Approved
trodelvy · sacituzumab govitecan · Trodelvy · IMMU-132 · sacituzumab-govitecan-hziy
2026-09-10
Data Confidence · High
Development Signal · Established
Antibody-drug conjugate
SN-38 (topoisomerase I inhibitor)
Hydrolyzable CL2A, DAR ~7.6
Humanized anti-TROP2 IgG1 (hRS7)
Very high DAR plus a deliberately unstable linker — extracellular SN-38 release gives bystander killing in TROP2-heterogeneous tumors.
구조화 데이터
Very high DAR plus a deliberately unstable linker — extracellular SN-38 release gives bystander killing in TROP2-heterogeneous tumors.
TROP2 downregulation, TOP1 mutation, and ABC-transporter payload efflux.
SN-38 (topoisomerase I inhibitor)
Hydrolyzable CL2A, DAR ~7.6
DAR 7.6
TROP2 · TROP2 is broadly expressed in epithelial tumors; no companion diagnostic is required in the label.
Manage neutropenia and diarrhea; UGT1A1 poor metabolizers at higher risk
TROP2 class leader by approval history; now facing Datroway and other TROP2 ADCs.
Unresectable locally advanced or metastatic TNBC after ≥2 prior therapies
2L+ TNBC; 3L+ HR+/HER2−
IV
10 mg/kg days 1 and 8 of a 21-day cycle
ORR ~35% in ASCENT
Manage neutropenia and diarrhea; UGT1A1 poor metabolizers at higher risk
TROP2 class leader by approval history; now facing Datroway and other TROP2 ADCs.
Anti-TROP2 antibody binds and internalizes; the hydrolyzable linker releases SN-38 both intracellularly and in the tumor microenvironment, inhibiting topoisomerase I and causing lethal DNA double-strand breaks.
immune-mediated antitumor effects regardless of tumor PD-L1 expression
Topoisomerase I inhibition → replication-fork collapse and apoptosis.
TROP2 is broadly expressed in epithelial tumors; no companion diagnostic is required in the label.
TROP2 downregulation, TOP1 mutation, and ABC-transporter payload efflux.
구조화 데이터
mice bearing HCC1806 TNBC xenograft
Human
ADC ~16 h; free SN-38 ~18 h
ORR and PFS; ctDNA dynamics exploratory
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA accelerated approval (mTNBC)
APPROVAL · 2020년 4월
FDA full approval on ASCENT
APPROVAL · 2021년 4월
HR+/HER2− breast cancer indication
APPROVAL · 2023년 2월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.